New Findings from Veneto Institute of Oncology in the Area of Colon Cancer Described (Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the...).

A recent study conducted by the Veneto Institute of Oncology in Padova, Italy, explored the use of nivolumab and relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (CRC). The study found that the combination of nivolumab and relatlimab provided durable clinical benefit and was well tolerated by patients. The primary end point of the study, the objective response rate, was 50%, and the disease control rate was 70%. The median progression-free survival was 27.5 months, and the median overall survival was not reached. The most common treatment-related adverse events were diarrhea, asthenia, and hypothyroidism. This study suggests that nivolumab and relatlimab may be an effective treatment option for patients with this type of CRC. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)